463 related articles for article (PubMed ID: 11959564)
21. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.
Keith KA; Hitchcock MJ; Lee WA; Holý A; Kern ER
Antimicrob Agents Chemother; 2003 Jul; 47(7):2193-8. PubMed ID: 12821467
[TBL] [Abstract][Full Text] [Related]
22. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.
Kern ER; Hartline C; Harden E; Keith K; Rodriguez N; Beadle JR; Hostetler KY
Antimicrob Agents Chemother; 2002 Apr; 46(4):991-5. PubMed ID: 11897580
[TBL] [Abstract][Full Text] [Related]
23. Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice.
Smee DF; Wandersee MK; Bailey KW; Wong MH; Chu CK; Gadthula S; Sidwell RW
Antiviral Res; 2007 Jan; 73(1):69-77. PubMed ID: 16712967
[TBL] [Abstract][Full Text] [Related]
24. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
Quenelle DC; Prichard MN; Keith KA; Hruby DE; Jordan R; Painter GR; Robertson A; Kern ER
Antimicrob Agents Chemother; 2007 Nov; 51(11):4118-24. PubMed ID: 17724153
[TBL] [Abstract][Full Text] [Related]
25. Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus.
Smee DF; Barnett BB; Sidwell RW; Reist EJ; Holy A
Antiviral Res; 1995 Jan; 26(1):1-9. PubMed ID: 7741517
[TBL] [Abstract][Full Text] [Related]
26. A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
Smee DF; Sidwell RW
Antiviral Res; 2003 Jan; 57(1-2):41-52. PubMed ID: 12615302
[TBL] [Abstract][Full Text] [Related]
27. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.
De Clercq E; Andrei G; Balzarini J; Leyssen P; Naesens L; Neyts J; Pannecouque C; Snoeck R; Ying C; Hocková D; Holý A
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):331-41. PubMed ID: 16247948
[TBL] [Abstract][Full Text] [Related]
28. Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.
Duraffour S; Andrei G; Topalis D; Krečmerová M; Crance JM; Garin D; Snoeck R
J Virol; 2012 Jul; 86(13):7310-25. PubMed ID: 22532673
[TBL] [Abstract][Full Text] [Related]
29. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge.
Roy CJ; Baker R; Washburn K; Bray M
Antimicrob Agents Chemother; 2003 Sep; 47(9):2933-7. PubMed ID: 12936997
[TBL] [Abstract][Full Text] [Related]
30. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice.
Andrei G; Gammon DB; Fiten P; De Clercq E; Opdenakker G; Snoeck R; Evans DH
J Virol; 2006 Oct; 80(19):9391-401. PubMed ID: 16973545
[TBL] [Abstract][Full Text] [Related]
31. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir.
Smee DF; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2001 Jan; 12(1):71-6. PubMed ID: 11437324
[TBL] [Abstract][Full Text] [Related]
32. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
33. Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection.
Knorr CW; Allen SD; Torres AR; Smee DF
Antiviral Res; 2006 Nov; 72(2):125-33. PubMed ID: 16782209
[TBL] [Abstract][Full Text] [Related]
34. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge.
Bray M; Martinez M; Smee DF; Kefauver D; Thompson E; Huggins JW
J Infect Dis; 2000 Jan; 181(1):10-9. PubMed ID: 10608745
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
Ruiz J; Beadle JR; Buller RM; Schreiwer J; Prichard MN; Keith KA; Lewis KC; Hostetler KY
Bioorg Med Chem; 2011 May; 19(9):2950-8. PubMed ID: 21493074
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
De Clercq E; Neyts J
Rev Med Virol; 2004; 14(5):289-300. PubMed ID: 15334537
[TBL] [Abstract][Full Text] [Related]
37. Metabolism of ganciclovir and cidofovir in cells infected with drug-resistant and wild-type strains of murine cytomegalovirus.
Okleberry KM; Warren RP; Smee DF
Antiviral Res; 1997 Jul; 35(2):83-90. PubMed ID: 9217245
[TBL] [Abstract][Full Text] [Related]
38. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.
De Clercq E
Clin Microbiol Rev; 2001 Apr; 14(2):382-97. PubMed ID: 11292644
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo inhibition of murine gamma herpesvirus 68 replication by selected antiviral agents.
Neyts J; De Clercq E
Antimicrob Agents Chemother; 1998 Jan; 42(1):170-2. PubMed ID: 9449280
[TBL] [Abstract][Full Text] [Related]
40. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections.
De Clercq E
Trends Pharmacol Sci; 2002 Oct; 23(10):456-8. PubMed ID: 12368068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
